Flare Capital Partners

Cancer care is too often fragmented, expensive, and overwhelming for patients and families.

We’re excited to announce that Flare Capital Partners has led the $28M Series A for Atlas Oncology Partners, a value-based oncology enablement platform embedding interdisciplinary care teams directly into community oncology practices.

Atlas is tackling one of the most complex and costly areas in healthcare by:
1️⃣ Embedding providers, nurses, patient navigators, and social workers into oncology practices
2️⃣ Delivering coordinated, patient-centered support during and beyond active treatment
3️⃣ Combining navigation, psychosocial care, proactive coordination, and expanded in-person + virtual access

By taking full medical cost risk and investing in partner practice operations, Atlas aligns patients, oncologists, and payers around what matters most: better outcomes, better experience, and lower avoidable costs.

As shared:

“Atlas Oncology Partners is addressing one of the most complex and costly areas of healthcare with a model that is deeply aligned with patients, oncologists, and payers at the forefront of value-based care. We are excited to lead their Series A and support Atlas as it scales the next-generation value-based oncology model — one that empowers community oncology groups to deliver coordinated, holistic care at scale and drives impactful clinical outcomes for patients and families impacted by cancer.”

Proud to partner with the Atlas and Rubicon Founders teams as they rethink how cancer care is delivered — and build a more coordinated, holistic future for patients navigating one of life’s hardest diagnoses.

📰 Read the news here: https://lnkd.in/eeGw3wR2

Ending the year on a very high note here at Flare Capital Partners! 🚀

We’re proud to celebrate four well-deserved promotions that reflect both the growth of our firm and the incredible impact of these leaders:

💫 Margaret Malone promotion to Partner
From Flare Scholar to Partner, Margaret has been a force since day one —leading FSV investments, serving on the board of Visana Health, advancing our company co-creation work with strategic LPs, and contributing across the venture ecosystem. A true rising star in healthcare VC.

💫 Uma Veerappan promotion to Vice President
A Booth grad and former Flare Scholar as well, Uma has played a leading role in early-stage investments, including in autonomous surgical robotics. Now based in Silicon Valley, she’s driving our ground game and helping shape our “hardware-delivers-AI” thesis.

💫 Amanda DiTrolio promotion to Vice President of Marketing & Platform
Amanda has sharpened our voice, scaled our community, and elevated how Flare shows up in the market — from our AI Advisory Council to Expert Roundtables to hosting our inaugural Compass Summit at Fenway Park. Amanda continues to bring order to our marketing and platform chaos.

💫 Caroline Glen promotion to Vice President of Investor Relations
Since joining, Caroline has brought gravitas, deep LP relationships, and a clear articulation of Flare’s opportunity at a transformative moment in healthcare — strengthening partnerships across our strategic and financial investor base.

These promotions are a hat tip to the talent, leadership, and collaboration that power Flare Capital. Please join us in congratulating Margaret, Uma, Amanda, and Caroline 👏

🚀 AI Advisory Council Member Spotlight: William Sheahan

William Sheahan is the chief innovation officer and a senior vice president of MedStar Health. He is also the executive director of the MedStar Institute for Innovation, a multidisciplinary team of associates who explore, build, and scale new ideas that shape the future success of MedStar Health.

Bill joined MedStar Health in 2013 as the executive director of the MedStar Health Simulation Training & Education Lab (SiTEL), which creates, deploys, and commercializes education products used at MedStar Health and across the country. In 2017, he became the founding executive director of the MedStar Telehealth Innovation Center to support digital care activities systemwide, which grew exponentially in response to COVID-19.

Bill has long been a champion for innovation across the system. He has most recently built and operated enterprise-wide automation, AI, and wellbeing infrastructure, and has extensive experience negotiating external strategic relationships. Bill has served as an advisor or board member to numerous companies, entrepreneurs, and executive teams, finding passion in refining product strategies and growing businesses.

💡 What excites you about being a founding member of the AI Advisory Council?

“I’m thrilled to join so many respected leaders on the Flare Capital AI Advisory Council as we strive to elevate health and healthcare delivery through the power of artificial intelligence. The potential of AI is extraordinary, yet its impact will be driven by our desire and ability to leverage the benefits of AI to transform the way we operate while also protecting against its limitations and risks. I look forward to deep conversations with this group that will undoubtedly further this important work.” – William Sheahan, SVP & Chief Innovation Officer, MedStar Health

📰 To learn more about the Flare Capital AI Advisory Council, you can read more here: https://flarecapitalpartners.medium.com/introducing-the-flare-capital-ai-advisory-council-transforming-the-future-of-healthcare-ai-873fe4efc595

At Flare Capital Partners, we are thrilled to announce our lead investment in the latest financing round for Peer AI, a pioneering agentic AI platform transforming life sciences regulatory documentation. Today, Peer AI announced $12.1 million in total funding, led by Flare Capital Partners and . We are also excited to be joined by our friends at Greycroft.

Documentation is a mission-critical workflow in drug development. Each new drug candidate generates 100,000 to 200,000 pages of regulatory documentation, yet the process remains manual, slow, and error-prone. Nearly one-third of FDA submissions contain data issues, and over 70% of applications are initially rejected due to incomplete or inaccurate data — leading to costly delays and risks.

Peer AI delivers the easiest path to AI-driven regulatory documentation. The company provides an agentic SaaS platform for comprehensive, connected document authoring, enabling life sciences companies to accelerate cycle times in drug development.

Read more on “Why We Invested” here: https://flarecapitalpartners.medium.com/investing-in-peer-ai-f03439689ffe